Abstract
We studied the effect of ramipril on urinary protein excretion and arterial pressure in a 27-year-old patient with GSD Ia and heavy proteinuria (2–3 g/24 h). Ramipril therapy resulted in an important reduction of proteinuria (0.3–0.5 g/24 h): no changes were observed in arterial pressure and renal function during the 12-month follow-up. We conclude that treatment with ramipril can be employed effectively and safely in GSD Ia patients with nephrotic-range proteinuria.
Similar content being viewed by others
REFERENCES
Baker L., Kern EFO, Olshan J, Goldfarb S, Dahlem ST (1988) Pilot study of captopril in patients with renal disease associated with glycogen storage disease, type I (GSD-I). Pediatr Res 23: 388A.
Chen YT, Coleman RA, Scheinman JI, Kolbeck PC, Sidbury JB (1988). Renal disease in type I glycogen storage disease. N Engl J Med 318: 7-11.
Ozen H, Ciliv G, Kocak N, Saltik IN, Yuce A, Gurakan F (2000) Short-term effect of captopril on microalbuminuria in children with glycogen storage disease type Ia. J Inherit Metab Dis 23: 459-463.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Pela, I., Donati, M.A. & Zammarchi, E. Effect of ramipril in a patient with glycogen storage disease type I and nephrotic-range proteinuria. J Inherit Metab Dis 24, 681–682 (2001). https://doi.org/10.1023/A:1012715110596
Issue Date:
DOI: https://doi.org/10.1023/A:1012715110596